NO931308L - Gaba reseptormodulatorer - Google Patents

Gaba reseptormodulatorer

Info

Publication number
NO931308L
NO931308L NO93931308A NO931308A NO931308L NO 931308 L NO931308 L NO 931308L NO 93931308 A NO93931308 A NO 93931308A NO 931308 A NO931308 A NO 931308A NO 931308 L NO931308 L NO 931308L
Authority
NO
Norway
Prior art keywords
receptor modulators
gaba receptor
insomnia
anxiety
gamma
Prior art date
Application number
NO93931308A
Other languages
English (en)
Other versions
NO931308D0 (no
NO308252B1 (no
Inventor
Michael Bruce Bolger
Kelvin Wellman Gee
Nancy Tsai-Yun Lan
Delia Belelli
Seid Mirsadeghi
Robert Hyde Purdy
Syed Hasan Tahir
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of NO931308D0 publication Critical patent/NO931308D0/no
Publication of NO931308L publication Critical patent/NO931308L/no
Publication of NO308252B1 publication Critical patent/NO308252B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO931308A 1991-08-13 1993-04-06 GABA-reseptor modulator og anvendelse derav NO308252B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/745,216 US5232917A (en) 1987-08-25 1991-08-13 Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
PCT/US1992/006699 WO1993003732A1 (en) 1991-08-13 1992-08-10 Gaba receptor modulators

Publications (3)

Publication Number Publication Date
NO931308D0 NO931308D0 (no) 1993-04-06
NO931308L true NO931308L (no) 1993-06-14
NO308252B1 NO308252B1 (no) 2000-08-21

Family

ID=24995739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931308A NO308252B1 (no) 1991-08-13 1993-04-06 GABA-reseptor modulator og anvendelse derav

Country Status (14)

Country Link
US (2) US5232917A (no)
EP (1) EP0554436B1 (no)
JP (1) JP3710470B2 (no)
KR (1) KR100287629B1 (no)
AT (1) ATE194287T1 (no)
AU (1) AU668880B2 (no)
CA (1) CA2093808C (no)
DE (1) DE69231221T2 (no)
DK (1) DK0554436T3 (no)
ES (1) ES2150917T3 (no)
GR (1) GR3034486T3 (no)
HK (1) HK1005986A1 (no)
NO (1) NO308252B1 (no)
WO (1) WO1993003732A1 (no)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
EP0701444B1 (en) * 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
WO1994028904A1 (en) * 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
WO1995004536A1 (en) * 1993-08-04 1995-02-16 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
US5677293A (en) * 1993-10-27 1997-10-14 Merrell Pharmaceuticals Inc. 16 unsaturated C17 heterocyclic steroids useful as steroid C17-20 lyase inhibitors
CA2139549A1 (en) * 1994-01-28 1995-07-29 Kazumi Ogata Corticoid derivatives and pharmaceutical and cosmetic compositions
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
ATE375993T1 (de) * 1994-02-14 2007-11-15 Euro Celtique Sa Androstane und pregane zur allosterischen modulation des gaba rezeptors
US5449795A (en) * 1994-02-14 1995-09-12 Cocensys, Inc. Process for synthesis of steroidal allylic tert. alcohols
US5994333A (en) * 1994-08-04 1999-11-30 Pherin Corporation Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
DE69519945T2 (de) * 1994-11-23 2001-06-07 Cocensys, Inc. Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
US6780853B1 (en) * 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
ES2235187T3 (es) * 1995-06-06 2005-07-01 Euro-Celtique S.A. Esteroides neuroactivos de las series del androstano y el pregnano.
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US5912266A (en) * 1996-08-21 1999-06-15 American Home Products Corporation Beta2 integrin cell adhesion molecule inhibitors
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
DE69927960T2 (de) * 1998-03-11 2006-07-20 Torbjörn Backström Epiallopregnanolon zur behandlung von krankheiten des cns
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
RU2243232C2 (ru) * 1999-04-29 2004-12-27 Еро-Сельтик С.А. 3альфа-гидрокси-3бета-метоксиметил-21-гетероцикл-замещенные стероиды, фармацевтическая композиция, способ облегчения или профилактики бессонницы или погружения в наркоз
US20020034772A1 (en) * 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
CA2395129C (en) * 1999-12-20 2008-12-16 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
GB9930562D0 (en) * 1999-12-23 2000-02-16 Boc Group Plc Partial oxidation of hydrogen sulphide
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2005105822A2 (en) * 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
AU2005330504B2 (en) * 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
CA2601715C (en) * 2005-03-24 2012-10-16 Emory University Dosage regimen for the treatment of a traumatic brain injury with progesterone
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
HUE026961T2 (en) * 2006-11-21 2016-07-28 Umecrine Cognition Ab Use of pregnant and androstane steroids for the manufacture of a medicament for the treatment of central nervous system disorders
AU2008265898B2 (en) * 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
AU2009219230A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2460350B (en) * 2008-04-25 2011-04-06 Kythera Biopharmaceuticals Inc Intermediates for the preparation of bile acids
CN103819525A (zh) * 2008-05-20 2014-05-28 梅克芳股份公司 甾族化合物
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ2009521A3 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
US8362286B2 (en) * 2009-08-13 2013-01-29 Marinus Pharmaceuticals, Inc. Method for making 3α-hydroxy, 3β- substituted-5α-pregnan-20-ones
EP2523666B8 (en) 2010-01-14 2016-04-06 Asarina Pharma AB A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
MX2013001704A (es) 2010-08-12 2013-06-28 Kythera Biopharmaceuticals Inc Composiciones sinteticas de acido biliar y metodos.
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
JP2014508784A (ja) * 2011-03-25 2014-04-10 ユニヴェルシテ ラヴァル １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤
CN106983754A (zh) * 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
DK2753632T3 (da) 2011-09-08 2023-07-10 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelse heraf
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
WO2013056181A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
CN102702126B (zh) * 2012-04-26 2014-08-06 四川大学华西医院 一种可用于麻醉剂的化合物
US20140057885A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
CN104822693A (zh) * 2012-10-29 2015-08-05 阿勒根公司 比马前列素和前列腺酰胺的磷酸酯
ES2621528T3 (es) 2012-11-28 2017-07-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de 3-(4’-sustituido)-bencil éter de pregnenolona
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
EP4086270A1 (en) 2012-12-18 2022-11-09 Washington University Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
WO2014134413A2 (en) * 2013-03-01 2014-09-04 Revlon Consumer Products Corporation Cyrrhetinic alkyl esters and protected derivatives thereof
TR201817995T4 (tr) 2013-03-13 2019-02-21 Sage Therapeutics Inc Nöroakti̇f steroi̇dler ve kullanim yöntemleri̇
MX2015012274A (es) 2013-03-14 2016-06-02 Univ Maryland Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
CN118754924A (zh) 2013-04-17 2024-10-11 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
JP6239091B2 (ja) 2013-04-17 2017-11-29 セージ セラピューティクス， インコーポレイテッド １９−ノル神経刺激性ステロイドおよびその使用方法
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
DK3021852T3 (da) * 2013-07-19 2021-03-15 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
ES2706180T3 (es) 2013-08-23 2019-03-27 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
US9629853B2 (en) 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
EP3705488B1 (en) 2014-05-29 2022-08-03 Sage Therapeutics, Inc. Neuroactive steroids, compositions and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
LT3206493T (lt) 2014-10-16 2020-08-25 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
CN118344424A (zh) 2014-10-16 2024-07-16 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
PT3224269T (pt) 2014-11-27 2020-06-01 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios do snc
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
EP3280420B1 (en) 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN104926916B (zh) * 2015-06-05 2016-08-24 郑祖兰 甾体化合物，含其药物组合物及其制备方法和应用
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
IL282048B2 (en) 2015-07-06 2024-09-01 Sage Therapeutics Inc Oxysterols and methods of using them
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
CN109195604B (zh) 2016-04-01 2023-11-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CN109689673B (zh) 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
BR112019008069A2 (pt) 2016-10-18 2019-09-03 Sage Therapeutics Inc oxiesteróis e métodos de uso dos mesmos
ES2952106T3 (es) 2016-10-18 2023-10-27 Sage Therapeutics Inc Oxisteroles y procedimientos de utilización de los mismos
JP7179739B2 (ja) 2017-02-10 2022-11-29 アサリナ ファーマ アーベー 医学的治療における使用のための３－β－ヒドロキシ－５－α－プレグナン－２０－オン
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
WO2019154257A1 (zh) * 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
JP2021519799A (ja) 2018-04-05 2021-08-12 アサリナ ファーマ エーピーエス 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
WO2019209850A1 (en) * 2018-04-23 2019-10-31 Reddy Doodipala Samba Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders
AR116659A1 (es) * 2018-05-04 2021-06-02 Acerus Pharmaceuticals Corp Derivados de neuroesteroides y usos de estos
EP3911331A4 (en) 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
EP3712161A1 (en) * 2019-03-19 2020-09-23 Bionice, S.L.U. Process for preparing high puritiy allopregnanolone and intermediates thereof
EP3976628A1 (en) 2019-05-31 2022-04-06 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
CN118027131A (zh) * 2019-08-07 2024-05-14 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
CN112341511A (zh) * 2019-08-09 2021-02-09 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物及其用途
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
EP4429669A1 (en) 2021-11-10 2024-09-18 Umecrine AB Steroid as a modulator of gabaa receptor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
DE1046039B (de) * 1957-09-07 1958-12-11 Schering Ag Verfahren zur Herstellung von Haloform-Anlagerungsprodukten der 3-Ketosteroide
US3061606A (en) * 1958-03-14 1962-10-30 Worcester Found Ex Biology Delta-4-pregnenolones and method
US3139445A (en) * 1958-05-23 1964-06-30 Schering Ag Haloform addition products of 17-formyl steroids
IT1051705B (it) * 1962-05-12 1981-05-20 Vismara Spa F Metodo per la preparazione di intermedi steroidali
US3132160A (en) * 1963-02-04 1964-05-05 Upjohn Co 3, 11-dioxygenated-17-desoxy-5beta-androstanes and processes therefor
US3385849A (en) * 1965-07-01 1968-05-28 Hoffmann La Roche Process for the preparation of 17beta-pregnanes from 17-oxo-steroids
GB1159434A (en) * 1965-08-16 1969-07-23 Glaxo Lab Ltd 11beta&;-Fluoro-19-nor-Steroids
US3665021A (en) * 1966-07-29 1972-05-23 Glaxo Lab Ltd 9alpha-unsubstituted-11beta-chloro-l9 nos-steroids
US3494943A (en) * 1967-12-29 1970-02-10 Rachelle Lab Inc Novel 9alpha-fluoro-11beta,17alpha,21-tri-hydroxy-16-hydroxymethyl - 6-(dihydroxy) methyl-1,4-pregnadiene-3,20-diones and derivatives thereof
US3637670A (en) * 1969-09-02 1972-01-25 Syntex Corp Intermediates and process for preparing useful 17alpha-hydroxy-20-keto and 17alpha 21-dihydroxy-20-keto pregnanes and derivatives thereof
CA895860A (en) * 1969-11-05 1972-03-21 Kruger Gunther PROCESS FOR THE PREPARATION OF 3.alpha.-HYDROXY-5.beta.-PREGNAN-20-ONE
US3816624A (en) * 1970-06-17 1974-06-11 Glaxo Lab Ltd Anaesthetic steroids
US3726864A (en) * 1970-07-20 1973-04-10 Glaxo Lab Ltd Novel 11 beta-chloro-19-norpregn-4-ene-3,20 diones and the 3,5-dienol ethers and esters thereof
GB1376892A (en) * 1970-11-12 1974-12-11 Glaxo Lab Ltd 2beta-substituted-3alpha-hydroxysteroids and their esters
GB1380248A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy steroids and esters thereof
US3943124A (en) * 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
US3900561A (en) * 1970-12-17 1975-08-19 Glaxo Lab Ltd Pharmaceutical compositions
BE776786A (fr) * 1970-12-17 1972-06-16 Glaxo Lab Ltd Composes de la serie du pregnane et de l'androstane a activite anesthesique
US3969345A (en) * 1970-12-17 1976-07-13 Glaxo Laboratories Limited 20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
GB1377608A (en) * 1970-12-17 1974-12-18 Glaxo Lab Ltd 3alpha-hydroxy or acyloxy pregnene-21-ethers
US3763195A (en) * 1971-02-09 1973-10-02 Glaxo Lab Ltd Novel 21-acyloxy-3alpha-hydroxy-5alpha-pregnone-11,20-diones
CH563406A5 (no) * 1971-04-23 1975-06-30 Ciba Geigy Ag
US3875148A (en) * 1971-07-09 1975-04-01 Glaxo Lab Ltd 9{60 -unsubstituted-11{62 -bromo-19-norsteroids
US3825565A (en) * 1971-11-02 1974-07-23 Glaxo Lab Ltd 3alpha-hydroxy-delta4-steroids of the pregnane series and esters thereof
GB1409239A (en) * 1971-11-11 1975-10-08 Glaxo Lab Ltd Process for the preparation of 3alpha-hydroxy-5alpha-steroids
BE791196A (fr) * 1971-11-11 1973-05-10 Glaxo Lab Ltd Nouveaux steroides, leur procede de preparation et leurs applications
US3959260A (en) * 1972-05-05 1976-05-25 Glaxo Laboratories Limited Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) * 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
US3989686A (en) * 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
DE2438020A1 (de) * 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
DE2526373C2 (de) * 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) * 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4424218A (en) * 1979-08-17 1984-01-03 Roussel Uclaf Novel 3 α-amino steroids
DE2950026C2 (de) * 1979-12-10 1982-05-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 11-Ketosteroiden
US4360470A (en) * 1980-10-22 1982-11-23 Hoffmann-La Roche Inc. Process and intermediates for the synthesis of Vitamin D3 metabolites and chenodeoxycholic acid
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
WO1989002272A1 (en) 1987-08-25 1989-03-23 Gee Kelvin W Compositions and methods for alleviating stress, anxiety and seizure activity
US5371077A (en) * 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them

Also Published As

Publication number Publication date
WO1993003732A1 (en) 1993-03-04
AU668880B2 (en) 1996-05-23
DE69231221D1 (de) 2000-08-10
EP0554436B1 (en) 2000-07-05
DE69231221T2 (de) 2000-11-09
ES2150917T3 (es) 2000-12-16
JP3710470B2 (ja) 2005-10-26
EP0554436A1 (en) 1993-08-11
HK1005986A1 (en) 1999-02-05
CA2093808A1 (en) 1993-02-14
DK0554436T3 (da) 2000-09-18
ATE194287T1 (de) 2000-07-15
CA2093808C (en) 2008-01-29
GR3034486T3 (en) 2000-12-29
NO931308D0 (no) 1993-04-06
JPH06501962A (ja) 1994-03-03
NO308252B1 (no) 2000-08-21
US5232917A (en) 1993-08-03
US5591733A (en) 1997-01-07
EP0554436A4 (no) 1994-01-12
KR100287629B1 (ko) 2001-10-22
KR930702005A (ko) 1993-09-08
AU2471992A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
ATE194287T1 (de) Gaba-rezeptor-modulatoren
IL112638A (en) 3alpha-HYDROXYLATED PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX9703826A (es) Androstano y series del pregnano para la modulacion alosterica del receptor gaba.
JPS51149480A (en) Servo device for n umerical control
ES476757A1 (es) Un procedimiento de preparacion de benzamidas heterociclicassustituidas.
JPS5248185A (en) Numerically controlling apparatus for lathe
DK0539803T3 (da) Triazaspirodecanon-methyl-chromaner til bekæmpelse af sygdomme i centralnervesystemet
NO174531C (no) Festeinnretning for forsyn til en linerygg, samt apparat for påsetting av forsyn
BG38637A3 (en) Method for preparing 2- exo- hydroxy- 7- oxabicyclo [2, 2, 1] heptanes
DK87382A (da) Fremgangsmaade til fremstilling af 1,4,5,6,7,8-hexahydro-2-alkyl-4-aryl-5-oxo-1,7-naphthyridin-3-carboxylsyreestere
JPS5313705A (en) Train service managing system
JPS53136216A (en) System for controlling running of trains
JPS5413115A (en) Train service managing and controlling system
JPS57132240A (en) Displaying method for displaying data on plural display devices
JPS51139214A (en) Bilateral catv system
JPS53120640A (en) Running control method for plating amount change in continuous electroplating line
JPS52102177A (en) Apparatus for automatically supplying feed stuff
JPS5315723A (en) Priority selection circuit
JPS5250653A (en) Input output handling device
JPS5323095A (en) Adjustable cable bracket
JPS5233056A (en) Source voltage regulator
JPS5366332A (en) Liquid crystal driving system
JPS5431243A (en) Clock control system
JPS51138672A (en) Process for prepari ng 4-benzoyl pyrazole derivatives
JPS53105946A (en) Transfer control system for time division data

Legal Events

Date Code Title Description
MK1K Patent expired